Shea Puttkammer, MD
Endocrinology, Diabetes & Metabolism · Richmond, VANPI 1619184835
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Merck at 24.2% of the total. Reporting peaked in 2019 at $5,685 and has fallen 57.9% since, to $2,392 in 2025. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 764 payments — averaging $31.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- Dexcom, Inc.$6K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Amgen$1K
- Abbott$750
- plus $8K from 50 others
What the payments were for
- Consulting fees$1,6107%
- Speaking & faculty fees$9,46439%
- Travel & lodging$750%
- Food & beverage$13,17354%
- Education$500%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$5,614
- STEGLATRO$5,460
- Wegovy$114
How this compares
$24,431 in reported general payments places this provider in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 296 | $471,528 |
| MounjaroTirzepatide | 200 | $238,640 |
| JardianceEmpagliflozin | 169 | $214,554 |
| TrulicityDulaglutide | 93 | $161,859 |
| Tresiba Flextouch U-200Insulin Degludec | 81 | $135,568 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 59 | $67,545 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $55,802 |
| JanuviaSitagliptin Phosphate | 47 | $46,639 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $42,114 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $39,688 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $37,898 |
| FarxigaDapagliflozin Propanediol | 44 | $36,260 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 33 | $35,690 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 48 | $31,980 |
| Humalog Kwikpen U-100Insulin Lispro | 83 | $30,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,403 | $477,072307 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,261 | $404,785307 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto Xr | $353 | $255,902213 claims |
| MerckJanumet Xr, Januvia, Janumet | $5,901 | $131,856122 claims |
| AstraZenecaFarxiga | $565 | $36,26044 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $561 | $26,22625 claims |
| Johnson & JohnsonInvokana | $39 | $16,95114 claims |
| Esperion Therapeutics, Inc.Nexletol | $249 | $14,99013 claims |
| AbbVieSynthroid | $206 | $12,141181 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $552 | $5,813428 claims |
| Cequr CorporationCequr Simplicity | $197 | $4,97912 claims |
| PfizerPremarin | $86 | $2,44012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Richmond
- Robert AdlerRichmond$10K
- Ranjodh GillRichmond$8K
- Robert CastellucciRichmond$7K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.